Blutplättchen und Hirudin

Erika Glusa

doi:10.1055/s-0038-1660298

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 1991; 11(03): 163-166
DOI: 10.1055/s-0038-1660298

Originalarbeiten

Schattauer GmbH

Blutplättchen und Hirudin

Erika Glusa

¹Institut für Pharmakologie und Toxikologie der Medizinischen Akademie Erfurt

› Institutsangaben

Abstract

Zusammenfassung

In biochemisch-pharmakologischen Untersuchungen haben sich native und rekombinante Hirudine als hochwirksame spezifische Inhibitoren der durch Thrombin ausgelösten Plättchenaggregation und Freisetzungsreaktion erwiesen. Im Gegensatz zum Heparin hat Hirudin keinen direkten Effekt auf die Plättchen. Hirudin ist ein besonders geeignetes Antikoagulans für Untersuchungen von Plättchenfunktionen bei physiologischen Kalziumionenkonzentrationen. Im mit Zitrat antikoagulierten Blut bzw. Plasma ist dagegen der Kalziumionengehalt vermindert, wodurch bestimmte Plättchenreaktionen wie die Thromboxanbildung begünstigt werden.

Volltext

Referenzen

LITERATUR
1 Basic-Micic M, Dechent CH, Rauschenbach CH, Breddin HK. On the effects of hirudins and low molecular weight heparins on platelet function. In: Strano A, Novo S. (eds) Advances in vascular pathology. Amsterdam; Elsevier: 1990: 289-94.
2 Basic-Micic M, Krupinski K, Breddin HK. r-Hirudin effects on various platelet functions. Angio Arch 1989; 18: 11.
3 Bell DN, Spain S, Goldsmith HL. Extracellular-free Ca⁺⁺ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma. Thromb Res 1990; 58: 47-60.
4 Brace LJ, Fareed J. An objective assessment of the interaction of heparin and its fractions with human platelets. Semin Thromb Hemost 1985; 11: 190-8.
5 Glusa E, Markwardt F. Adrenaline-induced reactions of human platelets in hirudin plasma. Haemostasis 1980; 09: 188-92.
6 Glusa E, Markwardt F. Studies on thrombin-induced endothelium-dependent vascular effects. Biomed Biochim Acta 1988; 47: 623-30.
7 Glusa E, Markwardt F. Platelet functions in recombinant hirudin-anticoagulated blood. Haemostasis 1990; 20: 112-8.
8 Hoffmann A, Markwardt F. Inhibition of the thrombin-platelet reaction by hirudin. Haemostasis 1984; 14: 164-9.
9 Hoffmann A, Markwardt F. Über die Auslösung der Serotoninfreisetzung aus Blutplättchen durch Thrombin. Biomed Biochim Acta 1984; 43: 321-36.
10 Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood 1990; 75: 399-406.
11 Keraly CL, Kinlough-Rathbone RL, Packham MA, Suzuki H, Mustard JF. Conditions affecting the responses of human platelets to epinephrine. Thromb Haemost 1988; 60: 209-16.
12 Knupp CL. Effect of thrombin inhibitors on thrombin-induced platelet release and aggregation. Thromb Res 1988; 49: 23-36.
13 Koike K, Holmsen H. Requirement for thrombin receptor occupancy during platelet secretion under aggregating and nonaggregating conditions. Thromb Haemost 1987; 58: 1053-9.
14 Lages B, Weiss HJ. Dependence of human platelet functional responses on divalent cations: Aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effects of chelating agents. Thromb Haemost 1981; 45: 173-9.
15 Lanza F, Beretz A, Stierle A, Hanau D, Kubina M, Cazenave JP. Epinephrine potentiates human platelet activation but is not an aggregation agent. Am J Physiol 1988; 255: H1276-H1288.
16 Märki WE, Wallis RB. The anticoagulant and antithrombotic properties of hirudins. Thromb Haemost 1990; 64: 344-8.
17 Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 1989; 15: 269-82.
18 Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989; 54: 377-88.
19 Markwardt F, Stürzebecher J, Glusa E. Antithrombin effects of native and recombinant hirudins. Biomed Biochim Acta 1990; 49: 399-404.
20 McNicol A, Gerrard JM, MacIntyre DE. Evidence for two mechanisms of thrombin- induced platelet activation: one proteolytic, one receptor mediated. Biochem Cell Biol 1989; 67: 332-6.
21 Nowak G, Glusa E. Pharmakologische Untersuchungen zur Adrenalin-Thrombin-in- duzierten Plättchenaggregation bei Hunden. Folia Haematol 1989; 116: 831-9.
22 Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol 1975; 228: 1757-65.
23 Packham MA, Bryant NL, Guccione MA, Kinlough-Rathbone RL, Mustard JF. Effect of the concentration of Ca²⁺ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 1989; 62: 968-76.
24 Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A₂ causes feedback amplification involving extensive thromboxane A₂ formation upon close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987; 70: 647-51.
25 Tam SW, Fenton JW, Detwiler TC. Dissociation of thrombin from platelets by hirudin: Evidence for receptor processing. J Biol Chem 1979; 254: 8723-5.
26 Walenga JW, Pifarre R, Fareed J. Recombinant hirudin as an antithrombotic agent. Drugs Future 1990; 15: 267-80.